Esophageal Cancer

The FDA has accepted for review Bristol Myers Squibb & Co Inc's (NYSE: BMY) supplemental marketing applications seeking approval for two Opdivo (nivolumab) based combo regimes for esophageal squamous cell carcinoma. The application cover Opdivo / Yervoy (ipilimumab) and...

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) announced interim results from the Phase 3 JUPITER-06 trial. Related: Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial. The trial is evaluating...

At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-eight patients were deemed evaluable. Zymeworks’ zanidatamab, combined with one of two chemotherapy regimens,...

Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations — Opdivo (nivolumab) plus chemotherapy, and Opdivo plus Yervoy (ipilimumab) in unresectable advanced or metastatic esophageal...

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval for Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) combined with chemotherapy for esophageal cancer. The...

Coherus BioSciences Inc's (NASDAQ: CHRS) partner Junshi Biosciences reported interim analysis from JUPITER-06 Phase 3 trial evaluating toripalimab in combination with paclitaxel/cisplatin chemo as first-line treatment of advanced esophageal squamous cell carcinoma...

Bristol-Myers Squibb Co (NYSE: BMY) has announced positive topline results from Phase 3 CheckMate 648 trial evaluating Opdivo (nivolumab) plus chemotherapy or Opdivo plus BMY's Yervoy (ipilimumab) in unresectable advanced or metastatic esophageal squamous cell...